Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy.

ABSTRACT:

Background

B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has demonstrated potent short-term efficacy in patients with relapsed/refractory multiple myeloma (R/R MM); however, long-term clinical data remain limited. Here, we report extended follow-up outcomes from our single-center experience.

Methods

Between August 20, 2018, and December 31, 2021, 11 patients with R/R MM received BCMA-targeted CAR-T-cell therapy at our center. Preconditioning consisted of cyclophosphamide and fludarabine chemotherapy, followed by infusion of 1-5×10⁶ CAR⁺ T cells/kg. We evaluated overall response rate (ORR), long-term efficacy, safety profiles, and their correlations with clinical/disease characteristics.

Results

The ORR w

SUBMITTER: Hao Y 

PROVIDER: S-EPMC12463850 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature